Literature DB >> 23932065

Cerebrospinal fluid and plasma clusterin levels in Parkinson's disease.

Karin D van Dijk1, Wesley Jongbloed, Johannes A Heijst, Charlotte E Teunissen, Henk J Groenewegen, Henk W Berendse, Wilma D J van de Berg, Robert Veerhuis.   

Abstract

Clusterin is a multifunctional chaperone protein that has repeatedly been linked to Alzheimer's disease (AD) pathogenesis and, more recently, also to Parkinson's disease (PD) by both genetic and proteomic analyses. Although clusterin is detectable in cerebrospinal fluid (CSF) and plasma, studies comparing clusterin levels in PD patients and controls have been scarce and yielded conflicting data. The aim of the present study was to determine whether CSF and/or plasma clusterin levels differ between PD patients and controls and are related to disease severity. We measured CSF and plasma clusterin levels in a group of 52 PD patients and in 50 age-matched neurologically healthy controls and found that clusterin levels in CSF and plasma were not different between the two groups. Furthermore, clusterin levels in CSF and plasma were not associated with disease duration, stage or severity. CSF clusterin levels did, however, correlate with CSF levels of total tau, phospho-tau and amyloid-β-42. We elaborate on the identified correlations between levels of clusterin and AD related proteins and on possible explanations for the discrepant findings in clusterin studies in PD so far.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Amyloid-β-42; Cerebrospinal fluid; Clusterin; Parkinson's disease; Plasma; Tau

Mesh:

Substances:

Year:  2013        PMID: 23932065     DOI: 10.1016/j.parkreldis.2013.07.016

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  14 in total

1.  Unfolded protein response-induced ERdj3 secretion links ER stress to extracellular proteostasis.

Authors:  Joseph C Genereux; Song Qu; Minghai Zhou; Lisa M Ryno; Shiyu Wang; Matthew D Shoulders; Randal J Kaufman; Corinne I Lasmézas; Jeffery W Kelly; R Luke Wiseman
Journal:  EMBO J       Date:  2014-10-31       Impact factor: 11.598

2.  Relationship between the plasma levels of neurodegenerative proteins and motor subtypes of Parkinson's disease.

Authors:  Jian Ding; Jiejin Zhang; Xixi Wang; Li Zhang; Siming Jiang; Yongsheng Yuan; Junyi Li; Lin Zhu; Kezhong Zhang
Journal:  J Neural Transm (Vienna)       Date:  2016-11-22       Impact factor: 3.575

3.  Cerebrospinal Fluid Particles in Alzheimer Disease and Parkinson Disease.

Authors:  Yue Yang; C Dirk Keene; Elaine R Peskind; Douglas R Galasko; Shu-Ching Hu; Eiron Cudaback; Angela M Wilson; Ge Li; Chang-En Yu; Kathleen S Montine; Jing Zhang; Geoffrey S Baird; Bradley T Hyman; Thomas J Montine
Journal:  J Neuropathol Exp Neurol       Date:  2015-07       Impact factor: 3.685

Review 4.  Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: toward a potential search for biomarkers for this disease.

Authors:  Félix J Jiménez-Jiménez; Hortensia Alonso-Navarro; Elena García-Martín; José A G Agúndez
Journal:  Front Cell Neurosci       Date:  2014-11-11       Impact factor: 5.505

Review 5.  What is the Clinical Significance of Cerebrospinal Fluid Biomarkers in Parkinson's disease? Is the Significance Diagnostic or Prognostic?

Authors:  Dana Kim; Jin Hui Paik; Dong-Woon Shin; Hak-Su Kim; Chang-Shin Park; Ju-Hee Kang
Journal:  Exp Neurobiol       Date:  2014-12-12       Impact factor: 3.261

Review 6.  Relationship between Apolipoprotein Superfamily and Parkinson's Disease.

Authors:  Lin Li; Ming-Su Liu; Guang-Qin Li; Jie Tang; Yan Liao; Yang Zheng; Tong-Li Guo; Xin Kang; Mao-Ting Yuan
Journal:  Chin Med J (Engl)       Date:  2017-11-05       Impact factor: 2.628

7.  Apolipoprotein E and clusterin inhibit the early phase of amyloid-β aggregation in an in vitro model of cerebral amyloid angiopathy.

Authors:  Yoshinori Endo; Kazuhiro Hasegawa; Ryo Nomura; Hidetaka Arishima; Ken-Ichiro Kikuta; Taro Yamashita; Yasuteru Inoue; Mitsuharu Ueda; Yukio Ando; Mark R Wilson; Tadanori Hamano; Yasunari Nakamoto; Hironobu Naiki
Journal:  Acta Neuropathol Commun       Date:  2019-01-28       Impact factor: 7.801

8.  CSF or serum neurofilament light added to α-Synuclein panel discriminates Parkinson's from controls.

Authors:  Linda P Oosterveld; Inge M W Verberk; Nour K Majbour; Omar M El-Agnaf; Henry C Weinstein; Henk W Berendse; Charlotte E Teunissen; Wilma D J van de Berg
Journal:  Mov Disord       Date:  2019-11-18       Impact factor: 10.338

9.  A different vision of translational research in biomarker discovery: a pilot study on circulatory mitochondrial proteins as Parkinson's disease potential biomarkers.

Authors:  Sandra I Anjo; Patrícia Valério Dos Santos; Luiza Rosado; Graça Baltazar; Inês Baldeiras; Diana Pires; Andreia Gomes; Cristina Januário; Miguel Castelo-Branco; Mário Grãos; Bruno Manadas
Journal:  Transl Neurodegener       Date:  2020-04-03       Impact factor: 8.014

10.  CSF Biomarkers Reflecting Protein Pathology and Axonal Degeneration Are Associated with Memory, Attentional, and Executive Functioning in Early-Stage Parkinson's Disease.

Authors:  Linda P Oosterveld; Tessa I Kuiper; Nour K Majbour; Inge M W Verberk; Karin D van Dijk; Jos W R Twisk; Omar M El-Agnaf; Charlotte E Teunissen; Henry C Weinstein; Martin Klein; Henk W Berendse; Wilma D J van de Berg
Journal:  Int J Mol Sci       Date:  2020-11-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.